Pulmonary adenocarcinoma with enteric differentiation: Dissecting oncogenic genes alterations with DNA sequencing and FISH analysis

Experimental and Molecular Pathology

Volumn 102, Issue 2, 2017, Pages 276-279

  Nottegar, Alessia ^a   Tabbò, Fabrizio ^b,c   Luchini, Claudio ^a,d   Guerrera, Francesco ^b   Gaudiano, Marcello ^b   Bria, Emilio ^a   Brunelli, Matteo ^a   Chilosi, Marco ^a   Inghirami, Giorgio ^c  

^a UNIVERSITY AND HOSPITAL TRUST OF VERONA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d SANTA CHIARA HOSPITAL   (Italy)

Author keywords

ALK; EGFR; Enteric; K RAS; Lung adenocarcinoma; PIK3CA

Indexed keywords

ADULT; AGED; ALK GENE; ARTICLE; BRAF GENE; CANCER CLASSIFICATION; CLINICAL ARTICLE; CODON; DNA SEQUENCE; EGFR GENE; EML4 GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; HUMAN; LUNG ADENOCARCINOMA; MALE; ONCOGENE; ONCOGENE K RAS; ONCOGENE N RAS; PIK3CA GENE; PULMONARY ADENOCARCINOMA WITH ENTERIC DIFFERENTIATION; SEQUENCE ANALYSIS; ADENOCARCINOMA; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MUTATION;

ANAPLASTIC LYMPHOMA KINASE; CODON; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN P21; PROTEIN TYROSINE KINASE;

ADENOCARCINOMA; AGED; CODON; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REARRANGEMENT; GTP PHOSPHOHYDROLASES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ANALYSIS, DNA;

EID: 85013909561     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2017.02.014     Document Type: Article

References (34)

1. Barton, S., et al. Predictive molecular markers of response to epidermal growth factor receptor (EGFR) family-targeted therapies. Curr. Cancer Drug Targets 10 (2010), 799–812.
2. Catasus, L., et al. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod. Pathol. 21 (2008), 131–139.
3. Cheng, L., et al. Molecular pathology of lung cancer: key to personalized medicine. Mod. Pathol. 25 (2012), 347–369.
4. Ding, L., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455 (2008), 1069–1075.
5. Dumont, A.G., et al. The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer. Chin. J. Cancer. 31 (2012), 327–334.
6. Garajová, I., et al. MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy. Clin. Epigenetics, 7, 2015, 129.
7. Handa, Y., et al. Pulmonary enteric adenocarcinoma. Gen. Thorac. Cardiovasc. Surg., 2015 (Epub ahead of print).
8. Inamura, K., et al. Pulmonary adenocarcinomas with enteric differentiation: histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas. Am. J. Surg. Pathol. 29 (2005), 660–665.
9. László, T., et al. Pulmonary enteric adenocarcinoma indistinguishable morphologically and immunohistologically from metastatic colorectal carcinoma. Histopathology 65 (2014), 283–287.
10. Lin, L.I., et al. Clinicopathological observation of primary lung enteric adenocarcinoma and its response to chemotherapy: a case report and review of the literature. Exp. Ther. Med. 11 (2016), 201–207.
11. Llobet, D., et al. Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints. J. Clin. Pathol. 62 (2009), 777–785.
12. Luchini, C., et al. Next generation histopathologic diagnosis: a lesson from a hepatic carcinosarcoma. J. Clin. Oncol. 32 (2014), e63–e66.
13. Luchini, C., et al. Specific expression patterns of epithelial to mesenchymal transition factors in gestational molar disease. Placenta 36 (2015), 1318–1324.
14. Luchini, C., et al. Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. Oncotarget 6 (2015), 39088–39097.
15. Luchini, C., et al. CD71 in gestational pathology: a versatile immunohistochemical marker with new possible applications. Appl. Immunohistochem. Mol. Morphol. 24 (2016), 215–220.
16. Luchini, C., Veronese, N., Yachida, S., Cheng, L., Nottegar, A., Stubbs, B., et al. Different prognostic roles of tumor suppressor gene BAP1 in cancer: a systematic review with meta-analysis. Genes Chromosom. Cancer 55 (2016), 741–749.
17. Ludovini, V., et al. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J. Thorac. Oncol. 6 (2011), 707–715.
18. Ma, Y.Y., et al. PIK3CA as an oncogene in cervical cancer. Oncogene 19 (2000), 2739–2744.
19. Metro, G., et al. Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report. Ecancermedicalscience, 9, 2015, 559.
20. Nottegar, A., et al. Pulmonary adenocarcinoma with enteric differentiation: immunohistochemistry and molecular morphology. Appl. Immunohistochem. Mol. Morphol., 2016 (In Press).
21. Ohashi, K., et al. Characteristics of lung cancers harboring NRAS mutations. Clin. Cancer Res. 19 (2013), 2584–2591.
22. Okudela, K., et al. PIK3CA mutation and amplification in human lung cancer. Pathol. Int. 57 (2007), 664–671.
23. Samuels, Y., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science, 304, 2004, 554.
24. Sasaki, H., et al. Nras and Kras mutation in Japanese lung cancer patients: genotyping analysis using LightCycler. Oncol. Rep. 18 (2007), 623–628.
25. Shayesteh, L., et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 21 (1999), 99–102.
26. Spoerke, J.M., et al. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin. Cancer Res. 18 (2012), 6771–6783.
27. Stojsic, J., et al. Intestinal type of lung adenocarcinoma in younger adults. Case Rep. Pulmonol., 2014, 2014, 282196.
28. Travis, W.D., et al. International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J. Thorac. Oncol. 6 (2011), 244–285.
29. Travis, W.D., et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. fourth ed., 2015, IARC Press, Lyon.
30. Tsao, M.S., Fraser, R.S., Primary pulmonary adenocarcinoma with enteric differentiation. Cancer 68 (1991), 1754–1757.
31. Tuononen, K., et al. ALK fusion and its association with other driver gene mutations in Finnish non-small cell lung cancer patients. Genes Chromosom. Cancer 53 (2014), 895–901.
32. Walls, M., et al. Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216. Clin. Cancer Res. 20 (2014), 631–643.
33. Wang, C.X., et al. Pulmonary enteric adenocarcinoma: a study of the clinicopathologic and molecular status of nine cases. Int. J. Clin. Exp. Pathol. 7 (2014), 1266–1274.
34. Wang, L., et al. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup. PLoS One, 9, 2014, e88291.